Silent PCSK9: RNAi Lipid- txo qis hauv The New Era

Thaum Lub Ob Hlis 27, 2026, raws li lub vev xaib rau kev sim tshuaj hauv Tebchaws Meskas, thawj theem ntawm kev sim tshuaj rau QLC7401 (RBD7022), tshuaj tshiab me me nucleic acid qhia los ntawm Qilu Pharmaceutical, tau pib ua haujlwm. Qhov no yog qhov kev vam meej tseem ceeb hauv cov lipids hauv tsev- txo qis kev kho siRNA tsom rau PCSK9, nqa cov kev kho tshiab rau cov neeg mob hyperlipidemia. Tus lej sim yog NCT07441317, txhawb nqa los ntawm Qilu Pharmaceutical.

Semaglutide hmoov CAS 910463-68-2

1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4

Peb muabSemaglutide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html

Nws yuav tshuaj xyuas qhov ua tau zoo thiab kev nyab xeeb ntawm QLC7401 ua ke nrog lipid- txo cov tshuaj ntawm kev txhaj tshuaj subcutaneous ntawm 100mg hauv kev kho mob thawj lossis sib xyaw hyperlipidemia nrog nce qis - ntom lipoprotein cholesterol (LDL-C). Tam sim no, kev sim tsis tau pib nrhiav neeg ua haujlwm. Thawj cov tshuaj RBD7022 ntawm QLC7401 yog tsim los ntawm Ruibo Biotechnology. Nws yog GalINAc conjugated siRNA tshuaj raws li nws tus kheej innovated RIBO GalSTAR @ daim siab lub hom phiaj xa khoom technology. Los ntawm lub hom phiaj thiab inhibiting cov protein tseem ceeb PCSK9 ntawm lipid metabolism, nws txhim kho lub peev xwm tshem tawm ntawm daim siab hlwb mus rau LDL -C thiab ua tiav qhov tseeb thiab ntev - ntev lipids - txo qis. Thaum Lub Kaum Ob Hlis 2023, Ruibo Biotechnology tau tso cai cov cai ntawm cov tshuaj hauv Suav teb av loj, Hong Kong, thiab Macau rau Qilu Pharmaceutical. Nrog rau cov txiaj ntsig zoo ntawm kev siv tshuab thiab kev lag luam, ob tog tau txhawb txoj kev nkag mus sai ntawm cov tshuaj mus rau theem kho mob tseem ceeb.

Thaum Lub Peb Hlis 1, 2026, Shanghai Minwei Biotechnology Co., Ltd. (tom qab no hu ua "Shanghai Minwei Biotechnology") tau txais kev pom zoo los ntawm National Medical Products Administration (tom qab no hu ua "NMPA") los tshaj tawm "Tsev Neeg Saib Xyuas Kev Pom Zoo Daim Ntawv Ceeb Toom" rau MWX401 kev txhaj tshuaj thawj zaug.

Kev txhaj tshuaj MWX401 yog ib qho tshuaj me me cuam tshuam RNA (siRNA) ntawm nws tus kheej tsim los ntawm Shanghai Minwei Biotechnology, nrog rau cov cuab yeej cuab tam thoob ntiaj teb. Nws tau xa daim ntawv thov kev kho mob mus rau CDE thaum Lub Kaum Ob Hlis 2025, nrog rau kev qhia txog kev kub siab thawj zaug. Cov kev tshawb fawb tsis tau soj ntsuam tau pom tias MWX401 tuaj yeem txo cov ntshav cov protein ntau, mRNA qib, systolic thiab diastolic ntshav siab hauv induced hypertension humanized nas; Nyob rau hauv spontaneously hypertensive rhesus liab, ib leeg subcutaneous kev tswj hwm ntawm cov koob tshuaj sib txawv ntawm MWX401 txhaj tshuaj tuaj yeem txo qis AGT tsiaj, nrog rau cov ntshav siab qis dua systolic thiab diastolic, nrog rau kev sib raug zoo hnub qub, zoo dua rau kev tswj hwm valsartan. Qhov txo qis hauv cov ntshav siab tuaj yeem tswj tau kom txog thaum kawg ntawm qhov kev sim, thiab cov nyhuv tshuaj hauv cov tsiaj yuav kav ntev li 12 lub lis piam. Lub caij no, kev ntsuam xyuas kev nyab xeeb tau pom tias MWX401 muaj kev nyab xeeb zoo.

Thaum Lub Peb Hlis 2, 2026, Bebret Pharmaceuticals tau tshaj tawm hnub no tias lub tuam txhab ywj pheej tsim thoob ntiaj teb thawj AGT / PCSK9 dual lub hom phiaj me me cuam tshuam RNA (siRNA) tshuaj BEBT-701 tau ua tiav nws thawj qhov kev tswj hwm (First Patient In, FPI) ntawm Xiangya Third Tsev Kho Mob ntawm Central South University, kos npe rau kev nkag mus rau hauv qhov project.

Thaum Lub Ob Hlis 2, 2026, BEBT-701 tau txais "Drug Clinical Trial Approval Notice" (No. 2026LP00318) tau pom zoo thiab muab los ntawm National Medical Products Administration (NMPA), thiab tau tso cai los ua theem 1-1 kev sim tshuaj rau kev kho mob ntawm cov roj cholesterol qis mus rau theem qis. (LDL-C). Pab pawg ua haujlwm ua tiav thawj qhov kev tso npe kawm hauv ib hlis tom qab kev pom zoo, kos npe rau tag nrho cov kev tshaj tawm thiab kev nce qib sai ntawm BEBT-701 kev tshawb fawb soj ntsuam raws li tau npaj tseg. Cov kev tshawb fawb tom ntej no yuav ntsuas qhov kev nyab xeeb, kev ua siab ntev, cov yam ntxwv ntawm cov tshuaj pharmacokinetic / pharmacokinetic, nrog rau cov kev cuam tshuam ntawm cov ntshav siab thiab cov lipid ntsig txog cov khoom no, muab kev tshawb fawb hauv paus rau kev tsim thiab kev siv cov kev tshawb fawb tseem ceeb yav tom ntej.

Thaum Lub Peb Hlis 2, 2026, Novo Nordisk tshaj tawm kev nqis peev ntawm 432 lab euros (kwv yees li 3.2 billion Danish kroner) txhawm rau nthuav nws lub hauv paus tsim khoom hauv tebchaws Ireland, uas yuav txhawb nqa Novo Nordisk qhov uas twb muaj lawm thiab yav tom ntej GLP-1 kho muaj peev xwm.
Nws tau tshaj tawm tias tag nrho cov phiaj xwm npog thaj tsam ntawm 45 daim av (18 hectares) thiab yuav tsim txog 500 txoj haujlwm tsim kho. Txoj haujlwm tsim kho tau pib thiab yuav maj mam ua kom tiav thaum kawg ntawm 2027 thiab 2028. Novo Nordisk xov xwm tshaj tawm hais tias qhov kev nqis peev no yog qhov tseem ceeb ntawm kev nqis peev hauv lub tuam txhab txoj kev txhim kho, ntxiv kev sib koom ua ke Novo Nordisk lub sijhawm ntev - kev cog lus rau kev kho mob tshiab hauv Ireland thiab thoob ntiaj teb. Nws yuav muab Novo Nordisk nrog rau kev tsim khoom ntxiv rau cov khoom siv hauv qhov ncauj, txhim kho cov khoom siv, thiab ua rau Ireland yog ib lub chaw tseem ceeb rau kev ua lag luam sab nraum Tebchaws Meskas. Qhov kev nqis peev no yuav raug siv rau kev txhim kho thiab kho dua tshiab ntawm cov chaw uas twb muaj lawm, nrog rau kev txhim kho lub peev xwm ntawm Novo Nordisk txoj kev kho qhov ncauj GLP-1.

Thaum Lub Peb Hlis 2, 2026, Beijing Zhipeptide Biopharmaceutical Technology Co., Ltd. Tsis ntev los no, Peptide Biotech tshaj tawm ua tiav ntau dua 500 lab yuan hauv Series C nyiaj txiag. Qhov kev pabcuam nyiaj txiag no yog coj los ntawm Aobo Capital (0rbiMed), nrog Qiming Venture Capital, zoo -paub kev lag luam nyiaj txiag, Wuyuan Capital, Xingze Capital, thiab Huagai Capital tom qab nplua. Cov tswv lag luam qub Taifu Capital, Lanchi Venture Capital, thiab Taiyu Investment txuas ntxiv nce lawv cov peev, thiab Haoyue Capital ua tus kws pab tswv yim nyiaj txiag tshwj xeeb rau cov nyiaj txiag no.

Peptide Biotech tau tsim qhov sib txawv ntawm kev ua yeeb yam ntev ntev, qhov ncauj peptides, thiab ntau- cov phiaj xwm kev teeb tsa hauv thaj tsam ntawm cov kab mob metabolic ntev kom ua tau raws li cov kev xav tau ntawm cov neeg mob sib txawv. Txoj kev siv thev naus laus zis hla fusion tseem yuav ua rau yav tom ntej ntawm kev kho cov kab mob metabolic. Nws cov khoom tseem ceeb, lub tswv yim tshiab GLP-1 RA txhua hli formulation Zovigliptin (ZT002) Txhaj, tab tom poob qhov hnyav theem kev sim tshuaj (HORIZON-1 txoj kev tshawb fawb) hauv Suav teb thiab xav tias yuav dhau los ua lub ntiaj teb thawj GLP-1 peptide yuav tsum tau noj ib hlis ib zaug. Yav dhau los, Zovigliptin tau pom tias muaj kev sib tw ua tau zoo thiab kev ua siab ntev nyob rau theem kuv qhov kev sim tshuaj, nrog rau qhov hnyav txog li 13.8% ntawm lub lim tiam 24, thiab tsis muaj theem siab pom. Tus nqi txiav tawm vim qhov tshwm sim tsis zoo ntawm plab hnyuv yog yuav luag xoom.

Raws li CIC, GLP-1 RA txhua hli kev tsim kho yuav tsum hloov kho qhov hnyav los ntawm kev tswj hwm txhua lub lis piam mus rau kev tswj hwm txhua hli, txhim kho kev ua raws li tus neeg mob zoo. Nws cia siab tias yuav suav txog li 26% ntawm lub ntiaj teb GLP-1 tshuaj lag luam muaj nqis txog $ 209.5 nphom los ntawm 2035.

Tsis tas li ntawd, lub tuam txhab lub qhov ncauj peptide GLP-1 receptor agonist ZT006 ntsiav tshuaj tau tshaj tawm Phase I kev sim tshuaj rau kev poob phaus hauv Suav teb; Ob lub hom phiaj tshiab cov khoom ZT003 txhaj tshuaj (GLP-1/FGF21) tab tom pib thaum sawv ntxov mus kuaj mob hauv Australia. Smeaglutide biological analog ZT001 tau mus txog kev koom tes nrog Tonghua Dongbao thiab Aimeike raws li kev txhawb nqa kev kho mob thiab kev lag luam ntawm cov ntshav qab zib thiab cov lus qhia poob phaus ib txhij.